Apotea AB (publ)CHIX:APOTES 18 3-Year RORE % is 29.18 as of Mar. 2026. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 606 Healthcare Providers & Services companies, Apotea AB (publ) ranks better than 76.24% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Apotea AB (publ)'s 3-Year RORE % for the quarter that ended in Mar. 2026 was 29.18%.
The industry rank for Apotea AB (publ)'s 3-Year RORE % or its related term are showing as below:
CHIX:APOTEs's 3-Year RORE % is ranked better than 76.24% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 0.195
vs CHIX:APOTEs: 29.18
Apotea AB (publ) (CHIX:APOTEs) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Apotea AB (publ) 3-Year RORE % Related Terms
Apotea AB (publ) 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Apotea AB (publ)'s 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) 3-Year RORE % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apotea AB (publ) 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Apotea AB (publ)'s 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Apotea AB (publ) (CHIX:APOTES) has a 3-Year RORE % of 29.18 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Apotea AB (publ) and its competitors. According to the industry distribution chart, Apotea AB (publ) ranks #144 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 23.8%.
Is Apotea AB (publ)'s 3-Year RORE % too high?
Apotea AB (publ)'s current 3-Year RORE % is 29.18. The Healthcare Providers & Services industry median 3-Year RORE % is 0.20. Apotea AB (publ)'s value of 29.18 is 14864.1% above this industry median. Based on the distribution chart, Apotea AB (publ) ranks #144 out of 606 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s 3-Year RORE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #144 out of 606 companies for 3-Year RORE %. This places Apotea AB (publ) in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 0.20. Apotea AB (publ)'s value of 29.18 is 14864.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.20, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apotea AB (publ)'s current 3-Year RORE % of 29.18 is 14864.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Apotea AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current 3-Year RORE % is 29.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current 3-Year RORE % of 29.18. The current 3-Year RORE % is 29.18 and 14864.1% above the Healthcare Providers & Services industry median of 0.20. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current 3-Year RORE % is 29.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score
Get the complete analysis for CHIX:APOTES
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:APOTES has been successfully added to your 
